Current Treatment for Multiple Myeloma
Menés respectivement sur 1 623 et 524 patients atteints d'un myélome multiple, ces deux essais évaluent, pour le premier, l'effcacité d'une combinaison lenalidomide-dexaméthasone chez les patients inéligibles à une greffe de cellules souches et, pour le second, l'efficacité du lenalidomide en traitement d'entretien
Résumé en anglais
In the past decade, we have witnessed dramatic changes in the treatment of multiple myeloma. Proteasome inhibitors such as bortezomib and carfilzomib target the ubiquitin pathway, resulting in cytotoxic injury due to disruption of protein degradation in myeloma cells. The immunomodulatory agents thalidomide, lenalidomide, and pomalidomide target myeloma cells through several mechanisms including direct cytotoxicity, antiangiogenic effects, and activation of antitumor immunity. Initial studies both with proteasome inhibitors and with immunomodulatory drugs in patients with relapsed or refractory disease have shown highly encouraging results. In patients 65 years of age or younger, high-dose chemotherapy with autologous stem-cell transplantation has . . .
